Retatrutide, a new dual activator of the GLP-1 receptor and glucose-dependent secreted polypeptide (GIP) binding site , is showing promising outcomes in early clinical trials . Recent research implies https://sociallytraffic.com/story6374014/retatrutide-emerging-research-and-projected-therapeutic-uses